Logo image of RGEN

REPLIGEN CORP (RGEN) Stock Price, Quote, News and Overview

NASDAQ:RGEN - Nasdaq - US7599161095 - Common Stock - Currency: USD

145.23  +3.83 (+2.71%)

After market: 145.23 0 (0%)

RGEN Quote, Performance and Key Statistics

REPLIGEN CORP

NASDAQ:RGEN (4/24/2025, 8:00:02 PM)

After market: 145.23 0 (0%)

145.23

+3.83 (+2.71%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High182.52
52 Week Low102.96
Market Cap8.16B
Shares56.18M
Float52.56M
Yearly DividendN/A
Dividend YieldN/A
PE98.13
Fwd PE83.43
Earnings (Next)04-29 2025-04-29/bmo
IPO04-29 1986-04-29


RGEN short term performance overview.The bars show the price performance of RGEN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10 15

RGEN long term performance overview.The bars show the price performance of RGEN in the last 1, 2 and 3 years. 1 year 2 years 3 years -2 -4 -6 -8 -10

The current stock price of RGEN is 145.23 USD. In the past month the price increased by 4.16%. In the past year, price decreased by -12.82%.

REPLIGEN CORP / RGEN Daily stock chart

RGEN Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 19.48 161.06B
DHR DANAHER CORP 26.38 140.59B
A AGILENT TECHNOLOGIES INC 20.15 30.51B
IQV IQVIA HOLDINGS INC 13.53 26.57B
MTD METTLER-TOLEDO INTERNATIONAL 26.12 22.40B
WAT WATERS CORP 28.7 20.27B
WST WEST PHARMACEUTICAL SERVICES 31.72 15.22B
ILMN ILLUMINA INC 31.68 12.28B
ICLR ICON PLC 10.42 12.05B
RVTY REVVITY INC 19.41 11.43B
AVTR AVANTOR INC 15.5 10.56B
QGEN QIAGEN N.V. 19.48 9.31B

About RGEN

Company Profile

RGEN logo image Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Company Info

REPLIGEN CORP

Building 1, Suite 100, 41 Seyon Street

Waltham MASSACHUSETTS 02453 US

CEO: Tony J. Hunt

Employees: 1783

Company Website: https://www.repligen.com/

Investor Relations: https://www.repligen.com/company/Investors/investors-overview

Phone: 17814499560

REPLIGEN CORP / RGEN FAQ

What is the stock price of REPLIGEN CORP today?

The current stock price of RGEN is 145.23 USD. The price increased by 2.71% in the last trading session.


What is the ticker symbol for REPLIGEN CORP stock?

The exchange symbol of REPLIGEN CORP is RGEN and it is listed on the Nasdaq exchange.


On which exchange is RGEN stock listed?

RGEN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for REPLIGEN CORP stock?

25 analysts have analysed RGEN and the average price target is 193.09 USD. This implies a price increase of 32.96% is expected in the next year compared to the current price of 145.23. Check the REPLIGEN CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REPLIGEN CORP worth?

REPLIGEN CORP (RGEN) has a market capitalization of 8.16B USD. This makes RGEN a Mid Cap stock.


How many employees does REPLIGEN CORP have?

REPLIGEN CORP (RGEN) currently has 1783 employees.


What are the support and resistance levels for REPLIGEN CORP (RGEN) stock?

REPLIGEN CORP (RGEN) has a resistance level at 145.24. Check the full technical report for a detailed analysis of RGEN support and resistance levels.


Is REPLIGEN CORP (RGEN) expected to grow?

The Revenue of REPLIGEN CORP (RGEN) is expected to grow by 10.14% in the next year. Check the estimates tab for more information on the RGEN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy REPLIGEN CORP (RGEN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REPLIGEN CORP (RGEN) stock pay dividends?

RGEN does not pay a dividend.


When does REPLIGEN CORP (RGEN) report earnings?

REPLIGEN CORP (RGEN) will report earnings on 2025-04-29, before the market open.


What is the Price/Earnings (PE) ratio of REPLIGEN CORP (RGEN)?

The PE ratio for REPLIGEN CORP (RGEN) is 98.13. This is based on the reported non-GAAP earnings per share of 1.48 and the current share price of 145.23 USD. Check the full fundamental report for a full analysis of the valuation metrics for RGEN.


What is the Short Interest ratio of REPLIGEN CORP (RGEN) stock?

The outstanding short interest for REPLIGEN CORP (RGEN) is 6.56% of its float. Check the ownership tab for more information on the RGEN short interest.


RGEN Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to RGEN. When comparing the yearly performance of all stocks, RGEN is a bad performer in the overall market: 70.25% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

RGEN Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to RGEN. RGEN has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RGEN Financial Highlights

Over the last trailing twelve months RGEN reported a non-GAAP Earnings per Share(EPS) of 1.48. The EPS decreased by -14.45% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -0.53%
ROE -0.75%
Debt/Equity 0.26
Chartmill High Growth Momentum
EPS Q2Q%33.33%
Sales Q2Q%7.58%
EPS 1Y (TTM)-14.45%
Revenue 1Y (TTM)23%

RGEN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to RGEN. The Buy consensus is the average rating of analysts ratings from 25 analysts.

For the next year, analysts expect an EPS growth of 17.62% and a revenue growth 10.14% for RGEN


Ownership
Inst Owners103.1%
Ins Owners0.5%
Short Float %6.56%
Short Ratio5.43
Analysts
Analysts78.4
Price Target193.09 (32.95%)
EPS Next Y17.62%
Revenue Next Year10.14%